Google researchers built an AI system that assesses the effects of every possible single-letter change across the human genome. Most such substitutions have no measurable impact, while a small subset produces meaningful biological effects. The work could help prioritize which genetic variants matter for disease research.
Google DeepMind has published a dataset that predicts the effects of roughly nine billion single-letter variations across the human genome. The resource is about one petabyte in size, roughly thirty times larger than the AlphaFold database. It was used to help identify a previously unexplained genetic cause in an epilepsy case.
Google DeepMind has published a dataset called the AlphaGenome Atlas that predicts the possible consequences of roughly nine billion single-letter variations in the human genome. The collection is about one petabyte in size, which the outlet notes is more than 30 times larger than the AlphaFold database. A case involving epilepsy is cited as an example of how the resource was used.
Google DeepMind has published AlphaGenome Atlas, a precomputed resource that scores the predicted effects of roughly nine billion genetic substitutions. The aim is to help researchers decide which variants to prioritize for experimental testing by tying predictions to biological mechanisms, with the DNM1 gene used as an illustrative case.
Google DeepMind has introduced the AlphaGenome Atlas, a resource that predicts the molecular impact of roughly 9 billion single-letter DNA changes across the human genome. Built on the AlphaGenome model, the atlas is intended to help researchers interpret how variants influence gene regulation and cellular function. It could assist in connecting genetic variants to disease and prioritizing candidates for further study.
WHY IT MATTERS ↘By precomputing predictions for ~9 billion variants, DeepMind converts an ML model into reusable research infrastructure that can undercut the cost of wet-lab variant triage and pressure startups selling variant-interpretation tools. It also sets a de facto benchmark for genomics models, extending DeepMind's model-led moat from protein structure into regulatory biology.